Inpharmatica obtains £31.25m funding from equity investors Dresdner Kleinwort Wasserstein, Advent Venture Partners and 3i.

Inpharmatica advised by Linklaters & Alliance (Jon Hayes). 3i and 3i Biosciences Investment Trust advised by Osborne Clarke (Alisdair Livingstone). Syndicate of investors advised by SJ Berwin (Perry Yam).